Celltrion applies sales approval of Herzuma to enter Japanese market

Celltrion announced it applied sales approval of Herzuma(CT-P6, generic name: trastuzumab), a self-developed anticancer antibody biosimilar, at the Japanese Ministry of Health, Labour and Welfare on the 11^th to enter the Japanese market.

Herzuma, an anticancer antibody biosimilar used to treat breast cancer and stomach cancer, references Herceptin developed by Genentech and sold by Roche. The ...